Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H17NO3 |
Molecular Weight | 223.2683 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)C(=O)C1=CC(OC)=C(O)C=C1
InChI
InChIKey=BQJODPIMMWWMFC-UHFFFAOYSA-N
InChI=1S/C12H17NO3/c1-4-13(5-2)12(15)9-6-7-10(14)11(8-9)16-3/h6-8,14H,4-5H2,1-3H3
Molecular Formula | C12H17NO3 |
Molecular Weight | 223.2683 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/4387399
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4387399
Ethamivan or etamivan, a respiratory stimulant was used in pulmonary emphysema.
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
10000 mg multiple, intravenous Highest studied dose Dose: 10000 mg Route: intravenous Route: multiple Dose: 10000 mg Sources: |
unhealthy, 21 years n = 1 Health Status: unhealthy Condition: barbiturate poisoning Age Group: 21 years Sex: M Population Size: 1 Sources: |
|
500 mg single, oral Highest studied dose |
unhealthy n = 5 Health Status: unhealthy Condition: CHRONIC RESPIRATORY DISEASE Population Size: 5 Sources: |
|
2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: CHRONIC RESPIRATORY DISEASE Population Size: 5 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (4 patients) Sources: Vomiting (1 patient) Muscle twitching (4 patients) Dysphoria (4 patients) Fatigue (4 patients) Dizziness (2 patients) Dyspnea (2 patients) Ear buzzing (1 patient) Vertigo (2 patients) Visual hallucinations (1 patient) Pruritus (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Ear buzzing | 1 patient | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: CHRONIC RESPIRATORY DISEASE Population Size: 5 Sources: |
Pruritus | 1 patient | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: CHRONIC RESPIRATORY DISEASE Population Size: 5 Sources: |
Visual hallucinations | 1 patient | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: CHRONIC RESPIRATORY DISEASE Population Size: 5 Sources: |
Vomiting | 1 patient | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: CHRONIC RESPIRATORY DISEASE Population Size: 5 Sources: |
Dizziness | 2 patients | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: CHRONIC RESPIRATORY DISEASE Population Size: 5 Sources: |
Dyspnea | 2 patients | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: CHRONIC RESPIRATORY DISEASE Population Size: 5 Sources: |
Vertigo | 2 patients | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: CHRONIC RESPIRATORY DISEASE Population Size: 5 Sources: |
Dysphoria | 4 patients | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: CHRONIC RESPIRATORY DISEASE Population Size: 5 Sources: |
Fatigue | 4 patients | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: CHRONIC RESPIRATORY DISEASE Population Size: 5 Sources: |
Muscle twitching | 4 patients | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: CHRONIC RESPIRATORY DISEASE Population Size: 5 Sources: |
Nausea | 4 patients | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: CHRONIC RESPIRATORY DISEASE Population Size: 5 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of ethamivan on alveolar ventilation in patients with chronic lung disease. | 1962 Dec 20 |
|
Effect of oral ethamivan on daily fluctuations of carbon dioxide tension in pulmonary emphysema with carbon dioxide retention. | 1969 Jan |
|
Respiratory depression in the coma of myxedema: treatment with ethamivan intravenously. | 1969 Oct |
|
Pentylenetetrazol and ethamivan effects on brain serotonin metabolism. | 1970 Jul 15 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4387399
Unknown
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 14:58:24 GMT 2023
by
admin
on
Fri Dec 15 14:58:24 GMT 2023
|
Record UNII |
M44O63YPV9
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47795
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
||
|
WHO-ATC |
R07AB04
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
||
|
WHO-VATC |
QR07AB04
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1074
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | |||
|
406087
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | |||
|
DB08989
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | |||
|
1174
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | |||
|
Etamivan
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | |||
|
24453
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID3023007
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | |||
|
SUB07259MIG
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | |||
|
92675
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | |||
|
100000082368
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | |||
|
304-84-7
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | |||
|
C100268
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | |||
|
206-157-3
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | |||
|
M44O63YPV9
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | |||
|
9363
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL1229908
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | |||
|
m5046
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
C76623
Created by
admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |